Bacillus Coagulans - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bacillus coagulans market size is projected to be USD 248.68 million in 2025, USD 260.56 million in 2026, and reach USD 330.28 million by 2031, growing at a CAGR of 4.84% from 2026 to 2031. This report is Segmented by by Strain (GanedenBC30 and GBI-30 6086, SNZ 1969, and More), by Form (Spore-Forming Powders, Capsules, and More), by Application (Dietary Supplements, Infant Nutrition, and More), by Distribution Channel (Direct Business-To-Business Sales, Specialty Health Stores, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Bacillus Coagulans Market Trends and Insights

Increasing Demand for Stable, Shelf-Ready Probiotics

Bacillus Coagulans spores do not depend on refrigerated distribution, which changes the logistics available to ingredient suppliers. A 2024 storage study reported more than 98% viability for BCP92 in gummies, oatmeal, brewed coffee, and peanut butter under food-storage conditions. This stability helps manufacturers serve locations with inconsistent refrigeration and reduces the operational risk associated with temperature excursions. It also supports specialty health stores and online channels that do not maintain pharmaceutical cold equipment throughout local delivery networks. The Bacillus Coagulans market can therefore reach applications where conventional mesophilic probiotics face higher delivery costs. Formulators can also use spores in products seeking simple ingredient lists without relying on preservative additions to protect the live culture.

Heat-Stable Probiotics for Processed Foods and Beverages

The Bacillus Coagulans market can address baking, pasteurization, and high-shear processing because the spores tolerate conditions that can reduce the survival of lactobacilli. A 2024 study of MTCC 5856 reported more than 98% spore survival in upma, tea, and coffee processing, and more than 99% retention in milk and white chocolate matrices. Kerry introduced a liquid BC30 format in 2025 for plant-based and dairy-alternative beverages. The format extends the options for UHT-processed and refrigerated products where powder dispersion can be a technical constraint. Heat tolerance also enables a single formulation to support protein-related positioning and live-culture positioning in sports beverages. This increases the relevance of spores in ready-to-drink products and functional foods that seek a credible microbiome-health component.

Strain-Specific Evidence and Authentication Gaps

The Bacillus Coagulans market faces a documentation gap between commercial availability and strain-specific clinical evidence. Regulators assess identity and safety at the strain level, including acquired antimicrobial resistance genes under the QPS approach. The changing use of Bacillus, Weizmannia, and Heyndrickxia names has added work to labels, dossiers, and trial records already in commercial use. Suppliers without proprietary dossiers may have difficulty defending product claims. Brand owners can respond by selecting named strains with stronger evidence. This makes entry harder for undifferentiated spore preparations and places pressure on generic positions in the Bacillus Coagulans market, especially where claims face review.

Other drivers and restraints analyzed in the detailed report include:

• Clinical Validation of Strain-Specific Digestive and Immune Benefits
• Restriction of Antibiotic Growth Promoters in Animal Nutrition
• Divergent Regulatory Requirements Across Regions

Segment Analysis

GanedenBC30 and GBI-30 6086 held 32.17% of Bacillus Coagulans market share in 2025. Their position reflects a broad regulatory clearance base and published work on gut health, immune function, protein absorption, and different population groups. Kerry’s Chinese adult study from 2025 added data for an East Asian cohort. Its Indonesian clearance in February 2026 expanded the available formulation pathway in Southeast Asia. LactoSpore and MTCC 5856 remain important competitors because of their clinical record. Food and Nutrition Research reported in June 2025 that MTCC 5856 supplementation improved symptoms of major depression and sleep quality in people with IBS. This supports a differentiated gut-brain and sleep-health position for the strain beyond its established digestive-health use.

Unique IS-2 is forecast to grow at a 6.07% CAGR through 2031 within the Bacillus Coagulans market size. Its positioning combines GRAS status, Health Canada NPN registration, and sports nutrition research on BCAA absorption, leg press strength, and vertical jump performance. Sanzyme is studying SNZ 1969 in school-aged children for immune, respiratory, and gastrointestinal outcomes during the 2025-2026 cold and flu season. Mitsubishi Chemical Group offers SANK 70258 and LACRIS-S, including a powder format described as stable to 120°C. These strains can support hot-fill and baked applications where processing conditions would otherwise limit probiotic selection. Leading strains are thus distinguished by regulatory files, human evidence, and application-specific performance rather than by volume alone or basic spore availability.

Spore-forming powders held 58.45% of the Bacillus Coagulans market share in 2025. This format remains the principal bulk ingredient for dietary supplements, functional foods, and animal feed. Its position is supported by the cost and handling advantages of unencapsulated spores for large-scale ingredient purchasing. Gummies and chews are forecast to grow at a 6.45% CAGR through 2031. Their growth reflects the ability of spores to withstand gelatin-setting and pectin-based manufacturing. This enables a delivery form that is less suitable for many conventional lactic acid bacteria during manufacture and shelf storage. The Bacillus Coagulans market, therefore, has a practical route into consumer-friendly supplement formats.

Encapsulated ingredients sit between bulk powders and finished consumer supplements. They can offer easier dosing and better dispersibility for buyers who do not make finished products. Capsules and tablets remain relevant when a product needs clear dose accuracy for IBS or immune positioning. These formats continue to serve pharmaceutical-grade uses and markets where consumers prefer a medicine-like presentation with familiar dosing expectations. Stick packs, sachets, and liquid products make up the other form category. Kerry’s 2025 liquid BC30 introduction addressed dispersion needs in plant-based and dairy-alternative beverages. The mix of formats allows the Bacillus Coagulans market to serve both industrial buyers and finished-product brands across different price points.

Complete Report Scope:

• By Strain
  • GanedenBC30 and GBI-30 6086
  • LactoSpore and MTCC 5856
  • SNZ 1969
  • Unique IS-2
  • SANK 70258 and LACRIS-S
  • Other Commercial Bacillus Coagulans Strains
• By Form
  • Spore-Forming Powders
  • Encapsulated Ingredients
  • Capsules
  • Tablets
  • Gummies and Chews
  • Others
• By Application
  • Dietary Supplements
  • Functional Foods and Beverages
  • Animal Feed and Feed Additives
  • Pharmaceutical Products
  • Infant Nutrition
  • Sports Nutrition
  • Others
• By Distribution Channel
  • Direct Business-to-Business Sales
  • Pharmacies and Drug Stores
  • Specialty Health Stores
  • Supermarkets and Hypermarkets
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.34% of the Bacillus Coagulans market share in 2025. The U.S. FDA GRAS notification framework is an important route for strain acceptance and a reference point for ingredient buyers assessing supplier documentation in other countries. The region also has sustained demand for dietary supplements, which creates a large established base for digestive and immune health products among mainstream consumers. Canada provides a separate formal pathway through the Natural Health Product Directorate and the Health Canada NPN process. Unique IS-2 has received Health Canada NPN registration. Mexico is still developing as a demand center, with digestive-health awareness and income growth supporting supplement adoption. Cross-border entry requires attention to Cofepris requirements and local documentation that can differ from United States product files.

Europe is governed by the Novel Food Regulation (EU) 2015/2283 and the EFSA QPS framework for strain-level safety assessment. EFSA’s 2026 QPS update confirmed Bacillus coagulans as the accepted name and treated Weizmannia coagulans and Heyndrickxia coagulans as synonyms. This substantially improves compliance clarity, supplier planning, and alignment between scientific records and customer-facing labels for suppliers that had changed labels during the 2022-2025 reclassification period and need consistent terminology across product documentation. Germany, the United Kingdom, and France support demand through established nutraceutical and functional-food sectors. The United Kingdom maintains a separate post-Brexit route, which may require an additional dossier for suppliers planning coordinated European launches. Sabinsa introduced ImmunoSpore in the European Union in May 2026 as a heat-inactivated MTCC 5856 postbiotic standardized to 15 billion spores per gram.

Asia-Pacific is forecast to grow at a 6.51% CAGR through 2031, the fastest regional rate in the Bacillus Coagulans market. Japan, China, and Southeast Asia are supported by evolving product rules and expanding local strain development, which strengthens regional capacity alongside consumer demand. China’s 2025 feed-additive standard provides a commercial framework for Bacillus Coagulans in livestock and poultry applications. India is both a manufacturing base and a growing consumption center, with Sabinsa and Sanzyme Biologics among the India-based participants.

List of Companies Covered in this Report:

• Archer-Daniels-Midland Company
• Aumgene Biosciences Private Limited
• BioGaia AB
• Bioriginal Food and Science Corp.
• Chr. Hansen Holding
• DuPont
• Kaneka
• Kerry Group plc
• Lallemand
• Lonza Group
• Mitsubishi Chemical Group Corporation
• Mystical Biotech Private Limited
• Nebraska Cultures Inc.
• Novonesis A/S
• Probi AB
• Probiotical S.p.A.
• Sabinsa Corporation
• Sanzyme Biologics Private Limited
• Syngen Biotech Co., Ltd.
• UAS Laboratories LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support